 | Up a level |
Chaccour, Carlos; Casellas, Aina; Hammann, Felix; Ruiz-Castillo, Paula; Nicolas, Patricia; Montaña, Julia; Mael, Mary; Selvaraj, Prashant; Duthaler, Urs; Mrema, Sigilbert; Kakolwa, Mwaka; Lyimo, Issa; Okumu, Fredros; Marathe, Achla; Schürch, Roger; Elobolobo, Eldo; Sacoor, Charfudin; Saute, Francisco; Xia, Kang; Jones, Caroline; ... (2023). BOHEMIA: Broad One Health Endectocide-based Malaria Intervention in Africa-a phase III cluster-randomized, open-label, clinical trial to study the safety and efficacy of ivermectin mass drug administration to reduce malaria transmission in two African settings. Trials, 24(1), p. 128. BioMed Central 10.1186/s13063-023-07098-2
Chaccour, Carlos; Casellas, Aina; Blanco-Di Matteo, Andrés; Pineda, Iñigo; Fernandez-Montero, Alejandro; Ruiz-Castillo, Paula; Richardson, Mary-Ann; Rodríguez-Mateos, Mariano; Jordán-Iborra, Carlota; Brew, Joe; Carmona-Torre, Francisco; Giráldez, Miriam; Laso, Ester; Gabaldón-Figueira, Juan C; Dobaño, Carlota; Moncunill, Gemma; Yuste, José R; Del Pozo, Jose L; Rabinovich, N Regina; Schöning, Verena; ... (2021). The effect of early treatment with ivermectin on viral load, symptoms and humoral response in patients with non-severe COVID-19: A pilot, double-blind, placebo-controlled, randomized clinical trial. EClinicalMedicine, 32, p. 100720. Elsevier 10.1016/j.eclinm.2020.100720
Chaccour, Carlos; Abizanda, Gloria; Irigoyen-Barrio, Ángel; Casellas, Aina; Aldaz, Azucena; Martínez-Galán, Fernando; Hammann, Felix; Gil, Ana Gloria (2020). Nebulized ivermectin for COVID-19 and other respiratory diseases, a proof of concept, dose-ranging study in rats. Scientific reports, 10(1), p. 17073. 10.1038/s41598-020-74084-y
Chaccour, Carlos; Ruiz-Castillo, Paula; Richardson, Mary-Ann; Moncunill, Gemma; Casellas, Aina; Carmona-Torre, Francisco; Giráldez, Miriam; Mota, Juana Schwartz; Yuste, José Ramón; Azanza, José Ramón; Fernández, Miriam; Reina, Gabriel; Dobaño, Carlota; Brew, Joe; Sadaba, Belen; Hammann, Felix; Rabinovich, Regina (2020). The SARS-CoV-2 Ivermectin Navarra-ISGlobal Trial (SAINT) to Evaluate the Potential of Ivermectin to Reduce COVID-19 Transmission in low risk, non-severe COVID-19 patients in the first 48 hours after symptoms onset: A structured summary of a study protocol for a randomized control pilot trial. Trials, 21(1), p. 498. BioMed Central 10.1186/s13063-020-04421-z
